Fig. 4

Microglia elimination with the CSF1R antagonist PLX5622 attenuated the therapeutic effects of PTS following I/R in vivo. A Overview of the timeline of in vivo experiments. Before MCAO/R, the mice were fed a PLX5622 (PLX) AIN-76A diet or AIN-76A chow for 14 days. B IF analysis of Iba1 staining in the brain after MCAO/R; the cell nuclei are shown in blue (DAPI). Scale bar = 20 μm, n = 5. C Representative images of TTC staining at 24 h after MCAO/R and quantitative analysis of the hemispheric infarct ratio (n = 5). Neurological tests, including assessment of the neurological deficit score (D) and performance in the hidden platform trial of the MWM (E), were conducted twice before surgery and at 1, 2 and 3 days after MCAO/R (n = 8). The data are presented as the means ± SEMs (n = 5). p < 0.05, versus the sham group; *p < 0.05, versus the MCAO + vehicle group; #p < 0.05, versus the MCAO/R + PTS group